Catalyst Wire Dossier Catalyst Wire Dossier

9-valent human papillomavirus vaccine (V503)

9-valent human papillomavirus vaccine · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 9-valent human papillomavirus vaccine (V503), covering 2014-12-22 to 2014-12-22. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). [Phase 3]

See pricing